Navigation Links
Regulus to Present at Future Leaders in the Biotech Industry Conference
Date:3/28/2013

LA JOLLA, Calif., March 28, 2013 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ: RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that Garry E. Menzel , Ph.D., Chief Operating Officer and Executive Vice President, Finance, will present a company overview at the 20th Annual Future Leaders in the Biotech Industry Conference on Friday, April 5, 2013 at 10:30 am EDT.  The conference is being held at the Millennium Broadway Hotel and Conference Center in New York City.

The presentation will be webcast at the time of the presentation and can be accessed on the Investor Relations page of the Company's website at www.regulusrx.com.  A replay of each webcast will be archived on the Company's website following the presentation date.

About Regulus

Regulus Therapeutics Inc. (NASDAQ: RGLS) is a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs. Regulus is leveraging a mature therapeutic platform based on technology that has been developed over 20 years. Regulus works with a broad network of academic collaborators and leverages the oligonucleotide drug discovery and development expertise of its founding companies, Alnylam Pharmaceuticals and Isis Pharmaceuticals. Regulus is advancing microRNA therapeutics toward clinical development in several areas, including oncology, fibrosis, hepatitis C and metabolic diseases. Regulus has formed strategic alliances with AstraZeneca, GlaxoSmithKline and Sanofi and a research collaboration with Biogen Idec.

For more information, please visit http://www.regulusrx.com.

Forward-Looking Statements

Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements associated with Regulus' expectations regarding future therapeutic and commercial potential of Regulus' business plans, technologies and intellectual property related to microRNA therapeutics being discovered and developed by Regulus.  Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "intends," "will," "goal," "potential" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Regulus' current expectations and involve assumptions that may never materialize or may prove to be incorrect.  Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks associated with the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs.  These and other risks concerning Regulus' programs are described in additional detail in Regulus' SEC filings.  All forward-looking statements contained in this press release speak only as of the date on which they were made. Regulus undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.


'/>"/>
SOURCE Regulus Therapeutics Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Regulus to Present at Cowen and Company 33rd Annual Healthcare Conference
2. Regulus Reports Fourth Quarter and Year-End 2012 Financial Results and Highlights
3. Regulus Announces Timing for Fourth Quarter and Year-End 2012 Financial Results Webcast and Conference Call
4. Regulus to Present at Two Upcoming Investor Conferences
5. Regulus Appoints Mark G. Foletta to its Board of Directors
6. Regulus Reports Third Quarter 2012 Financial Results and Recent Highlights
7. Regulus Announces Timing for Third Quarter 2012 Financial Results Webcast and Conference Call
8. Regulus Appoints Douglas E. Williams, Ph.D. to its Board of Directors
9. Regulus Announces $80.9 Million in Total Gross Proceeds from IPO and Other Recent Financial Transactions
10. Regulus Presents New Preclinical Data on miR-21 at Kidney Week 2012
11. Biogen Idec and Regulus Therapeutics Form Collaboration to Explore microRNA Biomarkers for Disease Monitoring and Response to Therapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/13/2017)... -- This morning, Stock-Callers.com draws attention to ... at yesterday,s closing bell: Clovis Oncology Inc. (NASDAQ: ... GALE ), and ACADIA Pharmaceuticals Inc. (NASDAQ: ... to develop technologies and products that combat debilitating and ... use less and cleaner energy, and provide safer, cleaner ...
(Date:1/13/2017)... Concord Medical Services Holdings Limited ("Concord Medical" ... leading specialty hospital management solution provider and operator of ... in China , announced that it ... Trust Co., Ltd. ("ZRT"). The Company signed ... Taihe Healthcare Fund in October 2016. The total amount of ...
(Date:1/13/2017)... 2017  Biologics Prescribers Collaborative (BPC) applauds ... for issuing final guidance calling for distinguishable ... is an important win for patients and ... pharmacovigilance, patient safety and transparency. ... FDA, we remain concerned with "random" suffixes called for ...
Breaking Medicine Technology:
(Date:1/13/2017)... Davis, California (PRWEB) , ... January 13, 2017 ... ... certain carbohydrates that raise blood sugar levels. Counting carbohydrates is as easy as ... not the only nutrient that affects blood sugar levels. Despite being sugar-free, proteins ...
(Date:1/13/2017)... (PRWEB) , ... January 13, 2017 , ... An inventor from Pahrump, Nev., used an ... "My urologist had me wear a Foley catheter and urine bag for a half year ... uncomfortable, so I decided that there should be a better way to do this." , ...
(Date:1/13/2017)... , ... January 13, 2017 , ... ... Sauna from the Finnleo factory in Cokato, MN, with the official send-off from ... and Maestro Osmo Vanska , Minnesota Orchestra’s Music Director, leading the official ...
(Date:1/13/2017)... ... January 13, 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh, ... of teaching people a way to peace, health and eternal joy. Yisrayl says he has ... peace. He adds that false accusations and persecution are nothing new in his world ...
(Date:1/13/2017)... (PRWEB) , ... January 13, 2017 , ... Sharon Kleyne, ... Sharon Kleyne Hour Power of Water, Global Climate Change and Your Health on Voice ... seems like we began only yesterday,” said Sharon Kleyne to her listening audience, “yet ...
Breaking Medicine News(10 mins):